For the past few months, NIGMS has been reviewing its HIV/AIDS grant portfolio. As the HIV/AIDS field has matured and the necessary research directions have become clearer, the HIV/AIDS-related grants we’ve supported have, appropriately, become more narrowly focused. Because of this, and after close consultation with leadership at the National Institute of Allergy and Infectious Diseases (NIAID), we’ve concluded that it’s in the best interest of the research to transition NIGMS’ HIV/AIDS portfolio to NIAID to allow improved scientific coordination, prioritization, and efficiency of management.Continue reading “NIGMS-Managed HIV/AIDS Research Transitioning to NIAID”
NIGMS has made MIRA awards to Established Investigators (EI) and Early-Stage Investigators (ESI) for three full Fiscal Years (FY). In this Feedback Loop post, we provide an analysis of application, review, funding, and demographic trends for the MIRA program.
For the first two rounds of EI MIRAs, eligibility was limited to well-funded NIGMS investigators: PIs with two or more NIGMS R01-equivalent awards or one NIGMS R01-equivalent award for >$400,000 in direct costs. For the FY 2018 EI competition and beyond, eligibility was expanded to include any investigator with a single PD/PI NIGMS R01-equivalent that is up for renewal. For the FY 2016 ESI MIRA competition, ESIs and New Investigators (NI) at the assistant professor or equivalent level were eligible, whereas eligibility was restricted to ESIs in subsequent rounds. As always, a PI can apply for an extension of ESI status for various life and career events, including childbirth.Continue reading “Application, Review, Funding, and Demographic Trends for Maximizing Investigators’ Research Awards (MIRA): FY 2016-2018”
When NIGMS issued PAR-17-094, Maximizing Investigators’ Research Award (R35), in December 2016, we opened the established investigator MIRA mechanism to all NIGMS grantees whose single-PI R01-equivalent grants were set to terminate in the same or subsequent fiscal year as the MIRA application. The purpose of this post is to remind you of important points to keep in mind if you are eligible to apply for a MIRA. Before applying, we strongly encourage you to contact your program director, who can advise you on whether MIRA is the best funding program for you and can help estimate a project budget if your application does well in peer review.
Some key points to know if you are considering applying for a MIRA grant:
Our Maximizing Investigators’ Research Award (MIRA) program is still relatively new, so it’s not surprising that NIGMS staff frequently hear misconceptions about it. This post dispels five common MIRA myths.
Myth 1: Once an investigator is awarded a MIRA, the budget will never increase.
MIRA budgets may increase. At the time of the competing renewal application, a principal investigator (PI) may request an increase in funding. MIRAs with modest budgets that have been very productive and score very well could receive budget increases. Study sections will be asked to look at budget requests, and NIGMS staff will make determinations based on the reviewers’ recommendations and available funds.
Myth 2: Early stage investigators will receive more funding for their labs if they get an R01 than if they get a MIRA.
A MIRA PI who is an early stage investigator (ESI) has a higher probability of receiving more NIGMS funding than a non-MIRA ESI. Most ESI MIRA investigators receive $250,000 in direct costs per year. A recent analysis found that the vast majority of ESIs who have received an NIGMS R01 are initially awarded $200,000 or less, and most do not go on to receive a second NIGMS R01 during the first five years of their initial award. Thus, the total NIGMS funding for most relatively new investigators is higher with a MIRA.
Myth 3: MIRA discourages collaborative research.
NIGMS strongly endorses collaborative research, and this extends to the MIRA program. However, the MIRA concept is based on the idea that NIGMS will provide support to individual investigators’ research programs. Collaborators are expected to work together because of their mutual interest in a problem. The collaborator, in most cases, will support his or her efforts with independent funding, not through a subcontract from the MIRA. In cases where a collaborator’s efforts are well-justified, essential to the research program of the MIRA and cannot be supported by the collaborator, a consortium agreement can be included in the competing application.
NIGMS also encourages scientifically productive international collaborative research efforts. However, NIGMS will only provide funding for a foreign consortium arrangement when the collaboration is essential to the PI’s research program, represents a unique scientific opportunity and cannot be supported by the collaborator.
Myth 4: MIRA PIs cannot apply for administrative supplements.
MIRA PIs are eligible for Research Supplements to Promote Diversity in Health-Related Research and may be eligible for other types of administrative supplements, such as equipment supplements offered by NIGMS through notices in the NIH Guide for Grants and Contracts. In rare situations, NIGMS may provide a supplement for a piece of equipment that could not have been anticipated at the time the application was submitted.
Myth 5: MIRA PIs cannot apply for NIGMS training grants or conference grants.
MIRA PIs are eligible to apply for grants that support research resources, training, workforce development or diversity building, clinical trials, selected cooperative agreements, SBIR/STTRs, conference grants and the portion of a center grant or a P01 that is strictly a core. In addition, a MIRA PI may receive grants from other NIH institutes or centers, although when making funding decisions NIGMS always considers an investigator’s other support, as described on our Funding Policies page.
More information, including answers to frequently asked questions, is on the MIRA page.